Abstract PS7-03: A first-in-human phase 1a/b trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant, allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer and other solid tumors: Results from the PIKASSO-01 study

Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Funda Meric-Bernstam(The University of Texas MD Anderson Cancer Center), Monica D. Ramstetter, Takako Eguchi Nakajima(St. Marianna University School of Medicine), Shigehisa Kitano(The Cancer Institute Hospital), Aurélie Lombard, Matthew P. Hanley, Manali Bhave(Northwestern University), Vincent Chau(Eli Lilly (United States)), Antonio Giordano(University of Siena), X. Cynthia(Washington University in St. Louis), Tira J. Tan(National Cancer Centre Singapore), Philippe L. Bédard(Princess Margaret Cancer Centre), Joyce O’Shaughnessy(Baylor University Medical Center), Shawn T. Estrem, Hope Rugo, Ruth O’Regan(University of Wisconsin Carbone Cancer Center), Nisha Unni(United States Nuclear Regulatory Commission), Mario Campone(Institut de Cancérologie de l'Ouest), Cristina Saura(Vall d'Hebron Hospital Universitari), Dejan Juric(Massachusetts General Hospital), Elgene Lim(St Vincent's Hospital Sydney), Hélène Vanacker, Lin Du(The University of Western Australia), Stephen Chia, Javier Cortes(Instituto Oncológico Dr. Rosell), Sherene Loi, François‐Clément Bidard(Inserm), Patrick Neven, Matthew P. Goetz(Mayo Clinic)

Clinical Cancer Research

June 13, 2025

Cited by 2

|New England Journal of Medicine|2020|3.1k

|New England Journal of Medicine|2022|2.5k

|International Journal of Clinical Oncology|2017|2.5k

|New England Journal of Medicine|2012|2.1k

|Cancer Discovery|2017|2k

Related Papers